Digital Biomarkers Map How Your Body Ages Across Eight Physiological Systems
A landmark review identifies wearable and digital biomarkers of aging across eight body systems, evaluating their validity, cost, and clinical utility.
Summary
Researchers from the Biomarkers of Aging Consortium conducted a comprehensive narrative review identifying digital biomarkers of aging measurable across ten physiological systems in community-dwelling adults. Using minimally or non-invasive capture methods, they found validated digital biomarkers across eight systems. Each biomarker was assessed for age-association, functional correlation, mortality prediction, generalizability, responsiveness to interventions, clinical outcome linkage, and cost-effectiveness. The review also catalogued registered clinical trials using these biomarkers as endpoints. Published in Lancet Healthy Longevity, this work highlights how digital health technologies — from wearables to smartphone sensors — are enabling longitudinal, real-world monitoring of biological aging, with significant implications for both research and personalized longevity medicine.
Detailed Summary
As global populations age, the need for scalable, accessible tools to monitor biological aging in real time has never been greater. Digital health technologies — wearables, smartphones, and connected devices — now generate rich physiological data that could serve as practical aging biomarkers, but a rigorous framework for evaluating them was lacking.
This narrative review, conducted by an international team under the Biomarkers of Aging Consortium, systematically searched for digital biomarkers of aging suitable for longitudinal use by community-dwelling adults. The scope spanned ten physiological systems, with the goal of classifying, characterizing, and evaluating each biomarker's scientific and practical merit.
Digital biomarkers were identified across eight of the ten physiological systems examined. Each was assessed against six criteria: age-association, functional association, mortality association, generalizability across populations, responsiveness to interventions, links to clinical outcomes, and cost-effectiveness in large-scale deployment. This multi-criteria framework provides a practical rubric for selecting biomarkers in both research trials and clinical longevity programs.
The review also identified registered clinical trials already using these digital biomarkers as outcome measures, signaling growing institutional confidence in their validity. This represents a meaningful step toward standardizing digital aging metrics in interventional research, including trials of longevity drugs, lifestyle interventions, and behavioral programs.
While the findings are promising, the review's narrative methodology means it does not provide quantitative effect sizes or head-to-head comparisons between biomarkers. Many digital biomarkers still lack large-scale validation across diverse populations. Nevertheless, this work offers a timely and comprehensive roadmap for integrating digital biomarkers into healthy aging research and personalized medicine.
Key Findings
- Digital aging biomarkers were identified across 8 of 10 physiological systems examined.
- Each biomarker was evaluated on validity, generalizability, intervention responsiveness, and cost-effectiveness.
- Minimally or non-invasive capture methods make these biomarkers suitable for community-dwelling adults.
- Registered clinical trials already use several identified digital biomarkers as primary or secondary endpoints.
- Continued technological development is needed to maximize clinical and population-level utility.
Methodology
This is a narrative review that systematically searched for digital biomarkers of aging across ten physiological systems. Biomarkers were restricted to those measurable via minimally or non-invasive methods suitable for longitudinal use in community-dwelling adults. Evaluation criteria included validity dimensions, generalizability, intervention responsiveness, clinical outcome associations, and cost-effectiveness.
Study Limitations
As a narrative review, the paper does not provide quantitative meta-analytic comparisons or effect sizes between biomarkers. Many identified biomarkers may lack validation across diverse ethnic, geographic, or socioeconomic populations. The review is limited by available published data and may not reflect the most cutting-edge unpublished or proprietary digital health technologies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.